Novo to Sue Aventis Over Long-acting Insulin – Claims Patent Infringement

On April 27, three days after glargine (Lantus) was approved by the U.S. Food and Drug Administration, Novo Nordisk filed a lawsuit with the Court of Dusseldorf in Germany against Aventis for patent infringement.

Novo claims that the production and sale of the 24-hour basal insulin infringes two German patents held by Novo Nordisk.

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.